Fluidigm Posts 21 Percent Q4 Sales Growth | GenomeWeb

NEW YORK (GenomeWeb News) – Fluidigm reported after the close of the market Tuesday that its fourth-quarter revenues increased 21 percent year over year, as the firm easily beat the consensus Wall Street estimates on the top and bottom line.

The South San Francisco, Calif.-based microfluidic systems developer had total revenues of $15.7 million for the three months ended Dec. 31, compared to $13 million for the fourth quarter of 2011. Analysts, on average, had expected revenues of $14.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.